Literature DB >> 11825111

Identification of numerical chromosomal changes detected by interphase fluorescence in situ hybridization in high-grade prostate intraepithelial neoplasia as a predictor of carcinoma.

Jaudah Al-Maghrabi1, Lada Vorobyova, A Toi, William Chapman, Maria Zielenska, Jeremy A Squire.   

Abstract

CONTEXT: High-grade prostate intraepithelial neoplasia (HPIN) is the most likely precursor of prostate cancer. The condition of many patients with a diagnosis of HPIN in prostate needle core biopsy could, if left untreated, progress to invasive cancer. Currently there is no available clinical, immunohistochemical, or morphologic criteria that are predictive of this progression.
OBJECTIVE: To determine whether chromosomal instability in these precursor lesions could increase their predictive value for cancer detection.
DESIGN: Dual-color interphase fluorescence in situ hybridization analysis was performed on archived prostate needle core biopsies from 54 patients with initial diagnosis of isolated HPIN and follow-up of 3 years or more. We used commercially available centromere probes for chromosomes 4, 7, 8, and 10. We had interpretable results in 44 patients as follows: (1) group A: 24 HPIN patients with persistent HPIN and/or benign lesions in the follow-up biopsies, and (2) group B: 20 HPIN patients with progression to prostate carcinoma.
RESULTS: Twenty-five percent of the patients in group B displayed numeric chromosomal aberrations. Only 8.3% of the patients from group A had chromosomal abnormalities (P =.1). The observed overall chromosomal changes in HPIN were higher than those in normal or hyperplastic epithelium, with a statistically significant difference (P <.05). All aberrations were detected in the form of chromosomal gain. Overall, the commonest aberration was gain of chromosome 8, followed by gains of chromosomes 7 and 10.
CONCLUSION: These results indicated that although no single numeric chromosomal abnormality could be assigned as a predictor of HPIN progression to carcinoma, the overall level of numeric chromosomal abnormalities shows a trend of elevation in HPIN patients whose condition subsequently progressed to carcinoma.

Entities:  

Mesh:

Year:  2002        PMID: 11825111     DOI: 10.5858/2002-126-0165-IONCCD

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  5 in total

1.  Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer.

Authors:  Anthony Michael Joshua; Bisera Vukovic; Ilan Braude; Sundus Hussein; Maria Zielenska; John Srigley; Andrew Evans; Jeremy Andrew Squire
Journal:  Neoplasia       Date:  2007-01       Impact factor: 5.715

2.  Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction.

Authors:  Andrew J Evans; Brenda L Gallie; Michael A S Jewett; Gregory R Pond; Kirk Vandezande; John Underwood; Yves Fradet; Gloria Lim; Paula Marrano; Maria Zielenska; Jeremy A Squire
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

3.  Efficiency of manual scanning in recovering rare cellular events identified by fluorescence in situ hybridization: simulation of the detection of fetal cells in maternal blood.

Authors:  Ahmed Emad; Seemi Ayub; Oumar Samassékou; Marie-Chantal Grégoire; Macoura Gadji; Aimé Ntwari; Josée Lamoureux; Francis Hemmings; Triantafyllos Tafas; Michael W Kilpatrick; Kada Krabchi; Régen Drouin
Journal:  J Biomed Biotechnol       Date:  2012-03-08

4.  The use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression.

Authors:  Simon Hughes; Maisa Yoshimoto; Ben Beheshti; Richard S Houlston; Jeremy A Squire; Andrew Evans
Journal:  BMC Genomics       Date:  2006-03-30       Impact factor: 3.969

5.  Identification of FISH biomarkers to detect chromosome abnormalities associated with prostate adenocarcinoma in tumour and field effect environment.

Authors:  Ying Zhang; Thomas Perez; Beth Blondin; Jing Du; Ping Liu; Diana Escarzaga; John S Coon; Larry E Morrison; Katerina Pestova
Journal:  BMC Cancer       Date:  2014-02-25       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.